New research provides hope for those with epilepsy

April 11, 2011, University of Reading

(PhysOrg.com) -- Groundbreaking research from the University of Reading could reduce the number and severity of seizures for epileptics.

Successful results from recent studies have shown that three different non-psychoactive cannabis extracts can significantly reduce . During the next few months, Reading researchers will be completing pre-clinical work which could enable the start of human trials.

affects around 1% of the global population and approximately 30% of people with epilepsy have seizures which are not controlled by conventional anticonvulsant drugs. Moreover, these drugs are associated with significant motor and cognitive side-effects that adversely affect the quality of life of individuals dependent upon their daily use.

A research group at the University of Reading, led by Dr Ben Whalley, Dr Claire Williams and Dr Gary Stephens from the Departments of Pharmacy and Psychology, is looking at whether individual compounds derived from cannabis, known as cannabinoids, could provide a solution to some of these difficult to treat seizures.

The group has recently published highly promising results which demonstrate that three different non-psychoactive compounds isolated from the cannabis plant have the potential to be used for the therapeutic control of seizures in epilepsy. Cannabidiol, D9-tetrahydrocannabivarin and GWP42006 were shown to significantly reduce the number and severity of seizure episodes in rats.

Dr Whalley said: "Other leading institutions around the world are investigating the involvement of the cannabinoids that our own bodies' produce (endocannabinoids') in seizure susceptibility, while others are examining how this system changes in response to seizures.

"However, the University of Reading is leading the search for therapeutic components of phytocannabinoids - cannabinoids extracted from the C. sativa plant that limit or abolish such seizures. We hope that these findings will lead to new, better tolerated and more effective treatments for people with epilepsy, reducing the number and severity of seizure episodes."

Whilst cannabis has been used medically and recreationally for thousands of years, it was not until the 1960s that the psychoactive component of , D9-THC, was identified. Subsequently, other components were isolated and identified and a small scale human trial conducted during the early 80s suggested that at least one of these components could be of use in seizure control. However, this initial finding has not been properly followed up and expanded upon until the present time.

More information: The research has been funded by a 1million grant from GW Pharmaceuticals plc and Otsuka Pharmaceutical Co, Ltd.

Related Stories

Recommended for you

Lab-on-a-chip delivers critical immunity data for vulnerable populations

April 25, 2018
For millions of displaced people around the world—many of them refugees, living in temporary shelters under crowded conditions—an outbreak of disease is devastating. Each year, the measles virus kills more than 134,000 ...

Want new medicines? You need fundamental research

April 25, 2018
Would we be wise to prioritize "shovel-ready" science over curiosity-driven, fundamental research programs? Would that set the stage for the discovery of more new medicines over the long term?

Implantable islet cells come with their own oxygen supply

April 25, 2018
Since the 1960s, researchers have been interested in the possibility of treating type 1 diabetes by transplanting islet cells—the pancreatic cells that are responsible for producing insulin when blood glucose concentration ...

'Incompatible' donor stem cells cure adult sickle cell patients

April 25, 2018
Doctors at the University of Illinois Hospital have cured seven adult patients of sickle cell disease, an inherited blood disorder primarily affecting the black community, using stem cells from donors previously thought to ...

Research explains link between exercise and appetite loss

April 24, 2018
Ever wonder why intense exercise temporarily curbs your appetite? In research described in today's issue of PLOS Biology, Albert Einstein College of Medicine researchers reveal that the answer is all in your head—more specifically, ...

Mammary stem cells challenge costly bovine disease

April 24, 2018
Mastitis is the most expensive disease in the dairy industry. Each clinical case can cost a dairy farmer more than $400 and damages both the cow's future output as well as her comfort.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.